ciprofloxacin (Q3939) / Bayer, Novartis - LARVOL DELTA

Session 4: Managing Dysgeusia, Neuropathy and Other Toxicities with Bispecific Antibodies in Multiple Myeloma : Episode 9: Managing Hematological Toxicities Associated with Bispecifics in MM (Cancer Network) - "Saad Z. Usmani, MD, MBA, FACP: This is something that our colleagues in the community will need to learn over time. I think managing cytopenias in general in solid oncology patients is different....We hope you found this Cancer Network Training Academy session on monitoring and managing dysgeusia, neuropathies, and other toxicities with bispecific antibodies in multiple myeloma [MM] to be useful and valuable to the treatment of your patients with MM. Thank you so much."

Video

Special Drug Use Investigation of Ciproxan Injection in Pediatrics (clinicaltrials.gov) - P=N/A; N=48; Completed; Sponsor: Bayer; Trial completion date: Dec 2018 ➔ Jun 2019

Clinical • Trial completion date

Mutant TET2 Allele Dosage Affects Response to 5-Azacitidine in Acute Myeloid Leukemia (ASH 2019) - "Consistent with our isogenic model data, we characterise biallelic somatic TET2 mutation in a patient with AML that was chemoresistant to anthracycline/cytarabine-based chemotherapy but acutely sensitive to 5-azacitidine, resulting in durable cytomorphological remission...In contrast, only 1 case with a TET2 mutation had a translocation affecting chromosome 4. In summary, our data argue in favour of using 5-azacitidine in patients with biallelic TET2-mutated AML and demonstrate the importance of considering mutant allele dosage in the implementation of personalised medicine for cancer patients."

ABCB1 • NPM1

Special Drug Use Investigation of Ciproxan Injection in Pediatrics (clinicaltrials.gov) - P=N/A; N=48; Completed; Sponsor: Bayer; Recruiting ➔ Completed

Clinical • Trial completion